Epigral Ltd Q4 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/txel5hs5npjnzw60slyjv2ko.pdf

Key Takeaways


Volume Recovery & Demand Environment

Milind Kotecha: "So to put it short, the price increase because of war will be majorly reflected in Q1 and not in Q4."

Chlorine Integration & Capacity Expansion

Milind Kotecha: "So definitely I'm sure that we will be freezing on something and announcing this year so that we can have a consistent growth beyond FY29, FY30 onwards."

Margins & Cost Structure

Milind Kotecha: "even if it ends, it will take time to stabilize and it's not going to happen in a -- immediate basis"

Renewable Energy & Power


Guidance & Commitments

CommitmentSpecificsTimeline
Volume growth10–12% volume growth, barring major war escalationFY27
ECH and CPVC capacity commissioningCapacity doubling commissionedQ2 FY27
Chlorine captive consumptionReach 90–95% (from 75% today)FY28 (at optimum utilization)
Chlorotoluene utilization~40% utilizationFY27
Chlorotoluene optimum utilization70–75% utilizationFY28
CPVC optimum utilization~75% utilizationFY28
ECH optimum utilization~80% utilizationFY28
Wind-solar hybrid share~15% of total power requirementOnce new 19.50 MW capacity at optimum
New greenfield project announcementProject freeze and public announcementThis year (calendar not specified)
Post-war realization stabilizationRealizations across all products to stabilize4–5 months after ceasefire holds

Key Metrics

MetricQ4 FY26
Revenue₹736 cr, highest ever, +22% QoQ
Volume growth15% QoQ, 14% YoY
EBITDA₹169 cr, +64% QoQ vs ₹103 cr in Q3
EBITDA margin23%, normalized on better plant utilization and raw material costs
PAT₹82 cr, vs ₹35 cr in Q3
PAT margin11%
Derivatives and specialty revenue share54%, vs 52% in Q3
Full-year FY26 revenue₹2,542 cr, down 1% YoY on 4% volume drop
Full-year FY26 EBITDA₹567 cr, vs ₹711 cr in FY25
Full-year FY26 EBITDA margin22%
Full-year FY26 PAT₹330 cr, includes one-time deferred tax benefit of ₹81 cr; excluding that, ₹252 cr vs ₹357 cr in FY25
Full-year FY26 ROCE16%; excluding CWIP of ₹451 cr, 17%
Net debt to EBITDA0.9x as on 31 Mar 2026, vs 0.7x previous year
Net debt₹508 cr, vs ₹489 cr previous year
Capex spent during the year₹394 cr
Cash generated from operations₹436 cr
Realized ECU (caustic soda)~₹30,000 in Q4; current ECU ~₹37,000 post-war
Caustic soda price increase30% to 35% vs pre-war levels
Chlorine captive consumption75% currently; expected to reach 90% to 95% after ECH and CPVC ramp-up
Wind-solar share in power consumption8% to 9% currently; expected ~15% after 19.50 MW addition
Volume growth target10% to 12% for FY27
Chlorotoluene utilizationMinuscule in FY26; expected ~40% in FY27, optimum 70% to 75% in FY28
CPVC and ECH current utilizationAround optimum, in the range of 65% to 80%
CPVC optimum utilization~75%
ECH optimum utilization~80%
Chloromethanes price hike~50% (post-quarter, to be reflected in Q1 FY27)
Full-year FY26 interest cost₹72 cr, higher than earlier guided ₹45 cr to ₹50 cr due to mark-to-market impact on foreign exchange derivative
Exports share4% to 5% of total revenue, mostly to Europe